Skip to Content

Optaflu

Active Substance: influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains: A/California/7/2009 (H1N1)pdm09 - like strain (A/Brisbane/10/2010, wild type) A/Switzerland/9715293/2013 (H3N2) - like strain (A/South Australia/55/2014, wild type) B/Phuket/3073/2013–like strain (B/Utah/9/2014, wild type)
Common Name: influenza vaccine (surface antigen, inactivated, prepared in cell cultures)
ATC Code: J07BB02
Marketing Authorisation Holder: Seqirus GmbH
Active Substance: influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains: A/California/7/2009 (H1N1)pdm09 - like strain (A/Brisbane/10/2010, wild type) A/Switzerland/9715293/2013 (H3N2) - like strain (A/South Australia/55/2014, wild type) B/Phuket/3073/2013–like strain (B/Utah/9/2014, wild type)
Status: Withdrawn
Authorisation Date: 2007-06-01
Therapeutic Area: Influenza, Human Immunization
Pharmacotherapeutic Group: Vaccines

Therapeutic Indication

Prophylaxis of influenza for adults, especially in those who run an increased risk of associated complications.

Optaflu should be used in accordance to official guidance.

The marketing authorisation for Optaflu has expired following the marketing authorisation holder's decision not to apply for a renewal.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide